Home > EAU20 Virtual

EAU20 Virtual


Custom content article

testeste

Meet the Trialist: Dr Andrew Blauvelt on the KNOCKOUT trial

KNOCKOUT Trial: Revolutionising psoriasis treatment with high-dose therapyMedicom interviewed Dr Andrew Blauvelt about the phase 2 KNOCKOUT trial (NCT05283135), which he presented as a late-breaking abstract at the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, CA, USA [1]. The 52-week results showed that a high induction dose of risankizumab is associated with significantly improved skin area severity…

AAD 2024 Highlights Podcast

https://conferences.medicom-publishers.com/wp-content/uploads/2024/03/AAD2024.mp3In this episode [14.28], Medicom’s correspondent covers 6 presentations from the annual meeting of the American Academy of Dermatology (AAD 2024), held in San Diego, CA, USA, from 8-12 March 2024.The topics discussed are: BTK inhibition – a novel approach to HS treatmentThe selective Bruton’s tyrosine kinase inhibitor remibrutinib was investigated as therapy for hidradenitis suppurative (HS). The phase 2…

Interview: How will the US 2024 presidential election affect healthcare?

Medicom Medical Publishers interviewed Jeanne Haggerty, a veteran healthcare lobbyist based in Washington D.C. She offered insights into the potential shifts in healthcare policy as the 2024 US elections approach. Representing a prominent multi-client lobbying firm with a significant focus on the healthcare and biopharma sectors, Haggerty brings over 25 years of experience to the table, and shares her insights…

Interview: Advancing Myeloma Care

Source: www.umcutrecht.nlIn recognition of March as Myeloma Awareness Month, Medicom is pleased to present an interview with Prof.Monique Minnema (UMC Utrecht, the Netherlands). Prof. Minnema has dedicated her career to advancing our understanding and treatment of multiple myeloma, the second most common blood cancer worldwide.Prof. Minnema, could you share a bit about your role and your focus in myeloma research?“I’m…

Impact of Treatment on Multiple Myeloma Outcomes: Real-World Experience

Physician’s Weekly – 11/03/2024 –The following is a summary of “Impact of Cytogenetic Abnormalities, Induction and Maintenance Regimens on Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: A Decade-Long Real-World Experience,” published in the December 2023 issue of Hematology by Thurlapati et al.Researchers started a retrospective study to assess the impact of high-risk…

JAK1 inhibitor meets primary endpoint in prurigo nodularis

Povorcitinib outperformed placebo in treating prurigo nodularis (PN). More than half of the participants in this phase 2 trial achieved a ≥4-point improvement in itch on the numeric rating scale (NRS4) on the highest study dose of povorcitinib.A novel management option for PN was explored in a phase 2 trial (NCT05061693) comparing the JAK1 inhibitor povorcitinib with placebo [1]. The…

Ritlecitinib shows marked efficacy in a difficult-to-treat AA population

In an analysis of the ALLEGRO trial, ritlecitinib therapy for up to 24 months led to a considerable regrowth of hair in patients with alopecia totalis and alopecia universalis. For the best possible results, alopecia areata (AA) patients should be treated as early as possible.Both alopecia totalis (AT) and alopecia universalis (AU) are difficult-to-treat subtypes of alopecia areata. In a…

Upadacitinib: A novel treatment possibility for vitiligo

In a phase 2 trial, the JAK1 inhibitor upadacitinib led to a fast improvement in repigmentation in patients with non-segmental vitiligo. After the 24-week, double-blind phase, participants showed continuous further pigmentation both in the face and the body.Previous research has shown that disruption of IFN-γ signalling by inhibiting the JAK/STAT pathway is an attractive therapeutic target for vitiligo. Therefore, the…

Long-term adverse events: JAK inhibitors mostly similar to traditional immunomodulators

The incidence rate assessment of venous thromboembolic events (VTE), serious infections, and malignancies, except for non-melanoma skin cancer (NMSC), found no significant difference between Janus kinase (JAK) inhibitors and non-JAK agents. The incidence rates for NMSC and major adverse cardiovascular events (MACE) were lower on JAK inhibitors.Ms Olivia Lamberg (University of Michigan, MI, USA) and colleagues gathered and summarised evidence…








Posted on